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Of five globally important VP7 (G) serotypes (G1–4 and 9) of group A rotaviruses (the single most important etiologic agents of infantile
diarrhea worldwide), G9 continues to attract considerable attention because of its unique natural history. Serotype G9 rotavirus was isolated
from a child with diarrhea first in the United States in 1983 and subsequently in Japan in 1985. Curiously, soon after their detection, G9
rotaviruses were not detected for about a decade in both countries and then reemerged in both countries in the mid-1990s. Unexpectedly,
however, such reemerged G9 strains were distinct genetically and molecularly from those isolated in the 1980s. Thus, the origin of the
reemerged G9 viruses remains an enigma. Sequence analysis has demonstrated that the G9 rotavirus VP7 gene belongs to one of at least three
phylogenetic lineages: lineage 1 (strains isolated in the 1980s in the United States and Japan), lineage 2 (strains first isolated in 1986 and
exclusively in India thus far), and lineage 3 (strains that emerged/reemerged in the mid-1990s). Currently, lineage 3 G9 viruses are the most
frequently detected G9 strains globally. We characterized a porcine rotavirus (A2 strain) isolated in the United States that was known to
belong to the P[7] genotype but had not been serotyped by neutralization. The A2 strain was found to bear serotype G9 and P9 specificities as
well as NSP4 [B] and subgroup I characteristics. By VP7-specific neutralization, the porcine G9 strain was more closely related to lineage 3
viruses than to lineage 1 or 2 viruses. Furthermore, by sequence analysis, the A2 VP7 was shown to belong to lineage 3 G9. These findings
raise intriguing questions regarding possible explanations for the emergence of variations among the G9 strains.
Published by Elsevier Inc.
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of approximately 440,000 deaths each year among children
b5 years of age, predominantly in the developing countries
(Parashar et al., 2003). In the United States alone,
approximately 500,000 physician visits, 50,000 hospital-
izations, and about 20 deaths are estimated to occur among
the approximately 2.7 million children b5 years of age
affected by rotavirus diarrhea yearly (Bresee et al., 1999;
Glass et al., 1994; Kapikian et al., 2001; Parashar et al.,
2003). Thus, the development and implementation of a safe05) 177–188
Y. Hoshino et al. / Virology 332 (2005) 177–188178and effective rotavirus vaccine has been a global public
health goal. Group A rotaviruses are also important
causative agents of diarrhea of the young of various
domestic animals including pigs (Saif et al., 1994).
Rotaviruses carry three important antigenic specificities:
group, subgroup, and serotype. Based on group specificity,
which is determined predominantly by VP6, rotaviruses are
divided into seven groups (A to G) (Kapikian et al., 2001).
Human rotavirus-associated infections are predominantly
caused by group A, and less commonly by group B or C;
thus, the emphasis of vaccine development has been targeted
at group A rotavirus-associated disease. Subgroup specific-
ity, which is also determined by VP6, has been used for
characterizing the antigenic properties of various rotavirus
isolates in epidemologic surveys. Most human rotaviruses
belong to either subgroup I or subgroup II (Kapikian et al.,
2001). Typing of subgroup specificity is performed by (i)
subgroup-specific monoclonal antibody-based ELISA
(Greenberg et al., 1983) or (ii) sequencing or restriction
fragment length polymorphism analyses of a 379-bp cDNA
amplicon of the VP6 gene (Iturriza-Go´mara et al., 2002a,b).
A determination of genotypes of NSP4, the gene 10 product
that has been reported to act as an enterotoxin (Ball et al.,
1996), is performed by sequencing of the gene. Genotypes
A, B and C NSP4s have been detected in human rotaviruses.
Rotavirus antigens that can induce neutralizing antibodies
have played a central role in research and development of a
rotavirus vaccine because neutralizing antibodies and their
type specificities appear to play an important role in
protection against many viral diseases. Rotavirus outer capsid
proteins VP7 and VP4 are independent neutralization and
protective antigens (Greenberg et al., 1985; Hoshino et al.,
1985; Offit et al., 1986) and thus a binary system of rotavirus
classification for the VP7 and VP4 neutralization specificities
has been established: the VP7 or G (because VP7 is a
glycoprotein) serotype and the VP4 or P (because VP4 is
protease-sensitive) serotype (Estes, 2001; Hoshino and
Kapikian, 1996; Kapikian et al., 2001). In order to circumvent
the lack of readily available reagents (i.e., type-specific high
titered polyclonal hyperimmune antisera) for serotyping and
to enable the typing of large numbers of rotavirus field
isolates, a G or P genotyping assay was developed in which
bgenotype-specificQ primers were employed in RT-PCR
(Gentsch et al., 1992; Gouvea et al., 1990). The numbers
assigned for G serotypes (types determined by neutralization
assay) and G genotypes (types determined by a nonsero-
logical assay) are identical, and thus a single number is used
(e.g., G1). However, the numbers assigned for P serotypes
and P genotypes are different; therefore, a P serotype is
designated with a P followed by the assigned number,
whereas the P genotype is designated by a P followed by
the assigned number in brackets (e.g., P1A[8]) (Estes, 2001;
Kapikian et al., 2001). If the genotype but not the serotype is
known, then the P is followed by the bracketed number only.
Interestingly, only 4 (G1, G2, G3 and G4) of 10 G serotypes
and only one (P1A[8] and P1B[4]) of 13 P serotypes found inhumans have repeatedly been reported to be of epidemio-
logical importance throughout the world (Gentsch et al.,
1996; Kapikian et al., 2001; Kirkwood and Buttery, 2003;
Koshimura et al., 2000; Palombo, 1999; Santos and Hoshino,
in press). Rhesus rotavirus (RRV)-based or bovine rotavirus
(UK or WC3)-based reassortant vaccines have been devel-
oped and are thus designed to cover such epidemiologically
important G and P types (Advisory Committee on Immuni-
zation Practices, 1999; Glass et al., 2004; Hoshino et al.,
2002, 2003; Midthun et al., 1985, 1986; Offit, 2002). Four
(G3, G4, G5, and G11) of 10 G types and two (P[6] and P[7])
of 8 P types detected in pigs are thought to be of
epidemiologic importance (Liprandi et al., 2003; Martella
et al., 2001; Saif et al., 1994).
A serotype of rotavirus outer capsid glycoprotein VP7 (G
serotype) has been defined based on a criterion that has been
used to establish a serotype of various viruses including
polioviruses, ECHO viruses, coxsackie viruses, and rhino-
viruses, namely a greater than 20-fold difference between
homologous and heterologous reciprocal neutralizing anti-
body titers (for reviews, see Hoshino et al., 1998). Serotypes
of outer capsid spike protein VP4 (P serotype) of selected
human rotaviruses were established by neutralization using
hyperimmune antiserum raised against each of four human
rotavirus VP4 proteins expressed by baculovirus recombi-
nants (Gorziglia et al., 1990). A criterion used to establish a
P serotype in that study was an eightfold difference between
homologous and heterologous reciprocal neutralizing anti-
body titers. A P subtype (P1A and P1B) was established by
the same authors based on a fourfold difference in
neutralizing antibody titers. However, today, it is possible
to determine P serotype using the same criterion (N20-fold
antibody difference) used for G typing (Hoshino and
Kapikian, 1996).
Serotype G9 viruses that have emerged recently as the
fifth globally common G type of clinical importance have
several unique characteristics (Arista et al., 2004; Bok et al.,
2001; Clark et al., 1987; Coulson et al., 1999; Cunliffe et al.,
2002; Das et al., 1993; Gentsch et al., 1993; Iturriza-Go´mara
et al., 2000; Kirkwood et al., 1993, 2002, 2003; Laird et al.,
2003; Martella et al., 2003; Nakagomi and Nakagomi, 2002;
Nakagomi et al., 1990; Oka et al., 2000; Ramachandran et
al., 1998, 2000; Santos et al., 2001, 2003; Unicomb et al.,
1995; Urasawa et al., 1992; Zhou et al., 2000, 2001, 2003).
For example, (i) prior to 1983, serotype G9 viruses were not
known; (ii) soon after their initial isolation in the US (in
1983) and Japan (in 1985), G9 viruses were not detected for
about a decade in both countries and reappeared in the mid-
1990s in both countries; (iii) unlike other globally common
G serotypes (G1–G4), which occur almost exclusively in
conjunction with either P1A[8] or P1B[4], G9 viruses have
been detected in association with a variety of P types
including P[4], P[6], P[8], P[9], P[11], and P[19]; and (iv) at
least three phylogenetic sequence lineages have been
reported to exist among the VP7 gene of G9 viruses. It is
noteworthy that (i) lineage 1 G9 viruses that include those
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world for the last 18–20 years but recently they have been
reported to occur in limited numbers in Japan (Zhou et al.,
2003); (ii) lineage 2 G9 viruses have been detected only
from asymptomatic neonates in India, thus far; and (iii) a
majority of G9 viruses that are prevalent around the world
today belong to lineage 3. Thus, it has been suggested that
the contemporary lineage 3 G9 strains are not direct
descendants of the lineage 1 G9 strains isolated in the
1980s (Laird et al., 2003). Recently, by analyzing a total of
40 G9 strains collected in the United States or India, Laird et
al. (2003) speculated that two U.S. strains (Om46 and
Om67) isolated in 1997–1998 may be the distant progenies
of the lineage 1 viruses since they bore VP7 gene equally
divergent in sequence from lineage 1 or lineage 3 VP7 gene.
It is also noteworthy that in addition to three major VP7
gene lineages, there exist a number of minor VP7 gene
lineages (Laird et al., 2003; Martella et al., 2003).
We have recently analyzed VP7 neutralization character-
istics of eight human G9 strains (2 lineage 1, one lineage 2
and 5 lineage 3) isolated in five different countries
(Bangladesh, Brazil, India, Japan, and United States) and
reported that (i) VP7 phylogenetic lineage-specific neutral-
ization specificities exist, and, moreover, (ii) lineage 1 G9
strains may be the most suitable as G9-specific vaccine
candidates because they induced the broadest cross-reactive
antibodies that neutralized all G9 viruses tested regardless of
their phylogenetic lineages (Hoshino et al., 2004). Thus, we
demonstrated in that study that not only nucleotide sequence
analysis but also VP7-lineage-specific serologic reagents are
powerful tools to study the phylogenetic origin of the VP7
gene/gene products of the G9 rotavirus isolates.
Ten of fifteen rotavirus G types are shared by humans
and animals. Of note is the report that describes the
detection of G9 viruses in pigs (in the United States and
Brazil) (Paul et al., 1988; Santos et al., 1999; Winiarczyk et
al., 2002) or sheep (in Scotland) (Fitzgerald et al., 1995).
The purpose of this study was threefold: (i) to characterize
serologically and molecularly the VP7 and VP4 of a porcine
rotavirus, designated as the A2 strain, which was one of two
porcine rotavirus strains in a commercial bivalent vaccine
for veterinary use in the United States (Hesse et al., 1993);
(ii) to analyze phylogenetic relationships of the VP7
between the porcine A2 strain and selected human G9
strains belonging to lineage 1, 2, or 3; and (iii) to determine
the electropherotype, subgroup specificity, and NSP4
genotype of the A2 strain.Fig. 1. Electrophoretic migration patterns of genomic RNAs of porcine G4
rotavirus Gottfried strain (lane 1), porcine G5 rotavirus OSU strain (lane 2),
porcine G11 rotavirus YM strain (lane 3), porcine G9 rotavirus A2 strain
(lane 4), human G9 rotavirus WI61 strain (lane 5), human G9 rotavirus F45
strain (lane 6), human G9 rotavirus AU32 strain (lane 7), human G9
rotavirus 116E strain (lane 8), human G9 rotavirus R44 strain (lane 9),
human G9 rotavirus R143 strain (lane 10), human G9 rotavirus US1205
strain (lane 11), human G9 rotavirus INL1 strain (lane 12), and human G9
rotavirus BD524 strain (lane 13) in 10% polyacrylamide gel.Results
Characterization of selected phenotypes of a porcine
rotavirus A2 strain
The A2 strain exhibited an electrophoretic pattern that
was distinct from that of (i) porcine rotavirus strainGottfried (P2B[6]:G4), OSU (P9[7]:G5), or YM (P9[7]:
G11) and (ii) various human G9 strains including WI61,
F45, AU32, 116E, US1205, R44, R143, BD524, and INL1
(Fig. 1). The A2 strain, which had a blongQ electrophoretic
pattern, was found to belong to subgroup I by ELISA (data
not shown).
Neutralization characteristics of the VP7 and VP4 proteins
of the A2 strain
Studies were carried out to determine the serotype
specificity of the A2 strain by neutralization assays in
which each of 3 guinea pig hyperimmune antisera raised to
the A2 virus was tested against selected prototype rotavirus
strains belonging to G1–G14. The three sera were also
tested against reassortant rotaviruses UK  A2 (P7[5]:
G,A2) and DS-1  A2 (P1B[4]:G,A2), each of which bore
only the VP7 gene from the A2 strain and the remaining
10 genes from either the bovine rotavirus UK or human
rotavirus DS-1 strain (Fig. 2). As shown in Table 1, each
of the three anti-A2 antisera was shown to contain high
levels of anti-A2 VP7 neutralizing antibodies. None of the
16 rotavirus strains representing the 14 established VP7
serotypes were neutralized significantly by any of the three
anti-A2 antisera. Two porcine strains OSU and YM and
one equine rotavirus strain L338 were neutralized to low
titers, which were N20-fold less than the homotypic titer.
Fig. 2. Electrophoretic migration patterns of genomic RNAs of bovine
rotavirus UK strain (lane 1), reassortant UK  A2 (lane 2), porcine
rotavirus A2 strain (lane 3), reassortant DS-1  A2 (lane 4), and human
rotavirus DS-1 strain (lane 5) in 10% polyacrylamide gel.
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in this one direction. In addition, the two reassortants that
contained only the VP7 of the A2 strain were each
neutralized to high titer, suggesting that the response was
to the VP7 and not to the VP4 of the A2 strain.
Next, we determined the reciprocal neutralization
pattern by examining the neutralization pattern of the A2
strain with hyperimmune antiserum raised to selected
prototype rotavirus strains belonging to each of the 14 G
types (Table 2). Antiserum to G1, G2, G7, G10, or G12
viruses did not neutralize the A2 virus. However, the A2
strain was neutralized (i) to high titers by antiserum to G5
(OSU) and G9 (WI61 and F45) viruses and (ii) to
moderate to low titers by antiserum to G3 (P), G4
(ST3), G6 (NCDV), G8 (69M), G11 (YM), G13 (L338),
and G14 (FI23) viruses. These results suggested that (i) the
A2 virus may be related via VP7 to either G5 or G9 and
(ii) an intermediate level of cross-reactivity observedbetween the A2 virus and antiserum to the YM (P9[7]:
G11) or L338 (P[18]:G13) may be due to the shared VP4
specificity.
To test these hypotheses, the A2 virus was tested
against antiserum raised against selected reassortants. As
shown in Table 2, the A2 virus was neutralized to high
titers by antiserum raised to each of the eight single VP7
gene substitution UK reassortants (UK  WI61, UK 
AU32, UK  116E, UK  R44, UK  R143, UK 
US1205, UK  INL1 or UK  BD524) each of which
bore only a single VP7 gene with G9 specificity (WI61,
AU32, R44, R143, US1205, INL1 or BD524) and the
remaining 10 genes from bovine rotavirus UK (Hoshino et
al., 2004), suggesting that the A2 virus was related to G9
viruses due to the shared VP7 specificity. In addition, the
A2 virus was not neutralized by anti-DS-1  OSU
(P1B[4]:G5) antiserum but was neutralized moderately by
antiserum to OSU  DS-1 (P9[7]:G2), indicating that the
cross-reactivity between the A2 and the OSU was due to
the shared P9 VP4 specificity. The latter observation
confirmed previous findings in which close genetic and
antigenic relationships between the A2 VP4 and the OSU
VP4 were demonstrated by RNA–RNA hybridization and
neutralization (Hesse et al., 1993). Furthermore, an
intermediate cross-reactivity observed between the A2
and YM (G11) or L338 (G13) was confirmed to be due
to the shared VP4 specificity since (i) the A2, OSU, and
YM share the same P genotype specificity (i. e., P[7]) and
(ii) the OSU VP4 and L338 VP4 are highly related
serotypically (Hoshino et al., unpublished observation).
Thus, the A2 strain shares VP7 neutralization specificity
with serotype G9. However, as noted previously in Table 1,
antiserum to A2 virus did not show any neutralizing
activities against human G9 strains WI61 and AU32 and
thus the A2 virus appeared to be a new serotype. This
apparent contradiction was examined further as follows: (i)
since in our previous study, antisera to lineage 3 G9 viruses
neutralized lineage 2 and 3 viruses to high titers but
exhibited marginal to very low neutralizing activities to
the lineage 1 prototype G9 strain WI61 (Hoshino et al.,
2004), we examined by neutralization assay three lineage 1,
one lineage 2, and five lineage 3 G9 strains against antisera
to A2 virus or UK  A2 (P7[5]:G,A2) reassortant; (ii) as
expected, three lineage 1 viruses were not neutralized or
neutralized poorly and all lineages 2 and 3 G9 strains were
neutralized to high titers by antisera to the A2 or reassortant
UK  A2 (Table 3), suggesting that the porcine G9 A2
strain shared high VP7 antigenic specificities with lineage 2
and 3 human G9 strains.
Nucleotide sequence as well as phylogenetic analyses of the
VP7, VP8*, and NSP4 genes of the A2 strain
The VP7 gene of A2 strain was 1061 bp in length, which
is common in G9 VP7 genes. The A2 strain demonstrated
higher nucleotide percent identity to lineage 3 than lineage 1
Table 1
Neutralization profiles of three guinea pig hyperimmune antisera raised to porcine rotavirus A2 strain toward selected prototype rotavirus strains belonging to
G1–G14
Rotaviruses against which guinea pig hyperimmune antisera were tested Antibody titera of guinea pig hyperimmune
antiserum to A2 strain
Reference
Strain Host Country
of origin
Year
collected
G
type
P type
[genotype]
Serum #1 Serum #2 Serum #3
Wa human USA 1974 1 1A[8] b80b b80 b80 Wyatt et al. (1982)
DS-1 human USA 1976 2 1B[4] b80 b80 b80 Wyatt et al. (1982)
P human USA 1974 3 1B[8] b80 b80 b80 Wyatt et al. (1982)
ST3 human UK 1975 4 2A[6] b80 b80 b80 Wyatt et al. (1983)
OSU porcine USA 1976 5 9[7] 160 320 80 Bohl et al. (1984)
UK bovine UK 1973 6 7[5] b80 b80 b80 Woode et al. (1975)
NCDV bovine USA 1967 6 6[1] b80 b80 b80 Mebus et al. (1971)
Ch2 chicken UK 1979c 7 ? b80 b80 b80 McNulty et al. (1980)
69M human Indonesia 1979/1981 8 4[10] b80 b80 b80 Matsuno et al. (1985)
WI61 human USA 1983 9 1A[8] b80 b80 b80 Clark et al. (1987)
AU32 human Japan 1986 9 1A[8] b80 b80 b80 Nakagomi et al. (1990)
B223 bovine USA 1983c 10 8[11] b80 b80 b80 Woode et al. (1983)
YM porcine Mexico 1983 11 9[7] 80 80 b80 Ruiz et al. (1989)
L26 human Philippines 1987/1988 12 1B[4] b80 b80 b80 Urasawa et al. (1990)
L338 equine UK 1991c 13 ?[18] 160 320 80 Browning et al. (1991a)
FI23 equine USA 1991c 14 4[12] b80 b80 b80 Browning et al. (1991b)
A2 porcine USA 1980s ? ?[7] 10,240 20,480 20,480 Hesse et al. (1993)
UK  A2 reassortant NAd NA ? 7[5] 10,240 20,480 20,480
DS-1  A2 reassortant NA NA ? 1B[4] 10,240 10,240 10,240
a Reciprocal of 60% plaque reduction neutralization antibody titer.
b A titer of b1:80 is considered background.
c Year published.
d NA = not applicable.
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acid (aa) sequence of the A2 strain with those of other G9
human strains used in this study is shown in Fig. 3. Certain
aa substitutions were shared (i) only between the A2 and
lineages 2 and 3 viruses (e.g., threonine at residue 220 and
asparagines at residue 242) and (ii) only between the A2 and
lineage 3 viruses (e.g., valine at residue 17, isoleucine at
residue 208 and lysine at residue 250), suggesting a close
genetic relatedness between the A2 VP7 and that of lineage
2 or 3 viruses. The A2 VP7 nucleotide sequence was shown
to cluster into phylogenetic lineage 3 (Fig. 4), confirming
further genetic close relatedness between them.
The highest degree of nucleotide identity of the A2 VP8*
gene was 92.2% with porcine P9[7] rotavirus OSU VP8*
gene, suggesting that the A2 VP4 belonged to P[7]
genotype.
The NSP4 gene of A2 strain was 750 bp in length.
Comparison of the deduced amino acid sequence of A2
NSP4 with published NSP4 sequences of representative
rotavirus strains showed the A2 NSP4 belonged to NSP4
genotype B (96.6% aa identity versus porcine OSU
NSP4[B]).
Previously, a close genetic relatedness between the
porcine A2 (P[7]:G9) strain and two porcine strains OSU
(P9[7]:G5) and Gottfried (P2B[6]:G4) was reported as
determined by whole genome RNA–RNA hybridization
(Hesse et al., 1993). In that study, nine hybrid bands were
formed between the A2 and OSU (the NSP1 and VP7 genesdid not hybridize) and nine hybrid bands were detected
between the A2 and Gottfried (the VP4 and VP7 genes did
not hybridize), demonstrating that the whole genome of the
A2 virus is of porcine rotavirus origin.Discussion
Rotavirus serotype G9 viruses continue to attract special
attention as one of the globally common G serotypes (G1–4
and 9) of clinical importance. That is because the G9 viruses
have a unique natural history and evolution in human
communities. For example, when these strains reemerged
after a decade of absence in the United States and Japan, the
genetic composition and molecular characteristics of such
reemerged G9 viruses were characteristically different from
those of the earlier isolates. For example, (i) the G9 viruses
isolated in the 1980s had a blongQ electropherotype with
P1A[8] and subgroup II specificities whereas the reemerged
G9 viruses had either a bshortQ or blongQ electropherotype
with P[4], P[6], [8], [9], [11], or [19] specificity in
association with subgroup I or II specificity and (ii) the
VP7 gene of the earlier isolates belonged to phylogenetic
lineage (lineage 1) distinct from that of the reemerged
isolates (lineage 3). Thus, such findings suggested that the
contemporary G9 viruses may have derived from a
phylogenetic progenitor distinct from that of the G9 viruses
isolated in the 1980s (Laird et al., 2003). It is of note that
Table 3
Antigenic relationships between porcine rotavirus A2 strain and nine hu an G9 tavirus strains belonging to lineage 1, 2, or 3
G9 rotavirus strains tested against guinea pig (GP) hyperimmune antise Antibody titera of GP antiserum to A2 or UK  A2 (P:7[5],G:A2) Reference
Strain Host Country
of origin
Year
collected
G
type
P ty
[gen ype]
E
typeb
VP7
gene
lineage
A2 (#1) A2 (#2) A2 (#3) UK  A2
WI61 Human USA 1983 9 1A[ L 1 b80 b80 b80 b80 Clark et al. (1987)
F45c Human Japan 1985 9 1A[ L 1 b80 160 320 160 see below
AU32 Human Japan 1986 9 1A[ L 1 b80 160 160 80 Nakagomi et al. (1990)
116E Human India 1986 9 [11] L 2 2560 2560 10,240 10,240 Gentsch et al. (1993)
R44 Human Brazil 1997 9 [9] L 3 2560 5120 5120 5120 Santos et al. (2001)
R143 Human Brazil 1999 9 [8] S 3 2560 10,240 2560 5120 Santos et al. (2001)
US1205 Human USA 1996/1997 9 [6] S 3 2560 20,480 5120 10,240 Ramanchandran et al. (1998)
INL1 Human India 1994 9 [6] L 3 5120 10,240 10,240 10,240 Ramanchandran et al. (2000)
BD524 Human Bangladesh 1995/1996 9 [8] L 3 2560 10,240 10,240 10,240 Ramanchandran et al. (2000)
A2 Porcine USA 1980s ? [7] L ? 10,240 10,240 10,240 40,960 Hesse et al. (1993)
a Reciprocal of 60% plaque reduction neutralization antibody titer.
b E = electropherotype, L = long, S = short.
c Ikegami et al., 1987.
Table 2
Antigenic characterization of porcine rotavirus A2 strain against hyperi une g ea pig antiserum raised to selected prototype rotavirus strains belongin to each of the 14 G types
Rotavirus Antibody titera of guinea pig hyperim une an rum raised to indicate rotavirus strain
Strain G
type
P
type
Wa
(P1A[8]:G1)
DS-1
(P1B[4]:G2) P1A[8 3)
ST3
(P2A[6]:G4)
OSU
(P9[7]:G5)
NCDV
(P6[1]:G6)
h2
?:G7)
69M
(P4[10]:G8)
WI61
(P1A[8]:G9)
A2 ? [7] b80 b80 160 160 10,240 160 b80 80 10,240
Rotavirus Antibody titera of guinea pig hyperim une an rum raised to indicate rotavirus strain or reassortant
Strain G
type
P
type
F45
(P1A[8]:G9)
B223
(P8[11]:G10)
M
P9[7]: 1)
L26
(P1B[4]:G12)
L338
(P?[18]:G13)
FI23
(P4[12]:G14)
S-1  OSU
1B[4]:G5)
OSU  DS-1
(P9[7]:G2)
A2 ? [7] 40,960 b80 640 b80 320 80 b80 2560
Rotavirus Antibody titera of guinea pig hyperim une an rum raised to indicate reassortant
Strain G
type
P
type
UK  WI61
(P7[5]:G9)
UK  AU32
(P7[5]:G9)
K  E
P7[5]: )
UK  R44
(P7[5]:G9)
UK  R143
(P7[5]:G9)
UK  US1205
(P7[5]:G9)
K  INL1
7[5]:G9)
UK  BD524
(P7[5]:G9)
A2 ? [7] 40,960 10,240 0,240 20,480 40,960 20,480 ,960 40,960
a Reciprocal of 60% plaque reduction neutralization antibody titer.
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Table 4
Percent nucleotide (below diagonal) and deduced amino acid (above diagonal) identity among the VP7s of porcine rotavirus A2 strain and nine human G9
rotavirus strains
Virus strain Host VP7 Percent identity with indicated virus belonging to
lineage
Lineage 1 Lineage 2 Lineage 3
WI61 F45 AU32 116E R44 R143 US1205 INL1 BD524 A2
WI61 human 1 – 98.5 97.9 92.6 95.1 95.7 95.7 94.2 93.3 95.4
F45 human 1 99 – 99.4 92.3 94.8 95.4 95.4 92.9 92.9 95.1
AU32 human 1 98.1 99.2 – 91.7 94.8 94.8 94.8 93.3 92.3 94.5
116E human 2 89.4 89.6 89.3 – 91.6 91.7 91.7 91.7 90.8 92.3
R44 human 3 89.4 89 89.6 88.8 – 98.8 98.8 95.4 95.7 96.6
R143 human 3 89.3 88.8 89.3 88.5 99.2 – 99.4 96 96.3 97.2
US1205 human 3 89.4 89 89 88.8 99 99.2 – 96 96.3 97.5
INL1 human 3 89.1 88.6 89 88.9 97.5 97.8 97.9 – 93.6 94.2
BD524 human 3 87.9 87.5 87.7 88.5 97.7 98 98 96.9 – 94.5
A2 porcine 3 90 89.7 90.2 89.1 92.3 95.4 95.1 94.2 94 –
Y. Hoshino et al. / Virology 332 (2005) 177–188 183lineage 2 viruses that were isolated first in 1986 have not
been detected outside of India. Today, the lineage 3 G9
viruses represent the fifth most common G type of clinical
importance in many parts of the world (for review, see
Santos and Hoshino, in press). In Australia, for example,
during the 2001–2002 season, the G9 serotype was the mostFig. 3. Comparison of the deduced amino acid sequence of the VP7s of the porcine
in this study. Three variable regions (VR1–VR3) that are not antigenic sites are ma
residues that have been demonstrated to be involved in the formation of antigen
(reviewed in Kapikian et al., 2001) are marked in red boxes.prevalent nationwide (40.4%) followed by G1 (38.9%)
(Kirkwood et al., 2002).
By analyzing G and P types of selected archival diarrheal
stool specimens collected in Philadelphia, PA (1994–1995,
n = 17; 1995–96, n = 171), Los Angeles, CA (1997–1997,
n = 50), and Providence, RI (1983–1997, n = 78), Jain et al.rotavirus A2 strain and nine serotype G9 human rotavirus strains employed
rked in black boxes. Six variable regions (VR4–VR9) and seven amino acid
ic sites (shown as letters in parentheses) through epitope mapping studies
Fig. 4. Phylogenetic comparison of the VP7 nucleotide sequence of the A2
strain with those of nine human G9 strains employed in this study
determined by the unweighted pair group method with arithmetic mean
program. Numbers above branches are bootstrap nucleotide percentage
values. Number in brackets after each rotavirus strain indicates the VP7
gene phylogenetic sequence lineage. The GenBank accession numbers for
the VP7 sequence are as follows: 116E, L140720; WI61, AB180970; F45,
AB180967; AU32, AB045372; INL1, AJ250277; BD524, AJ250543; A2,
AB180972; R44, AF438227; US1205, AF060487; R143, AF274969.
Y. Hoshino et al. / Virology 332 (2005) 177–188184(1999) concluded that the year 1995 may mark the first
appearance of the lineage 3 G9 viruses in the United States.
More recently in 2003, by analyzing a total of 40 G9 viruses
isolated in India or the United States, Laird et al. (2003)
reported that the lineage 3 G9 viruses were detected as early
as 1993 in India.
In the present study, we showed a porcine rotavirus
(designated the A2 strain), which had not been VP7
serotyped previously but had been genotyped as belonging
to genotype P[7] (Hesse et al., 1993), bore a serotype
P9:G9, NSP4[B] and subgroup I specificities. Of note is the
finding that prototype G9 human rotavirus strain WI61
(isolated in the United States in 1983) as well as two
Japanese G9 strains F45 and AU32 (isolated in 1985 and
1986, respectively) were not neutralized or neutralized
inefficiently by anti-A2 antisera although reciprocally anti-
WI61 antiserum or anti-AU32 antiserum neutralized sig-
nificantly the A2 virus (a one-way neutralization relation-
ship). However, antiserum to A2 neutralized significantly
other human G9 strains tested including 116E (isolated in
India), R44 and R143 (isolated in Brazil), US1205 (isolated
in the US), INL1 (isolated in India), and BD524 (isolated in
Bangladesh). In addition, antiserum raised to each of the
latter six G9 strains neutralized the A2 virus significantly (a
two-way neutralization relationship). Recently, we reported
that (i) G9 viruses belonging to lineage 2 (strain 116E) or
lineage 3 (strains R44, R143, US1205, INL1 and BD524)
are distantly related based on the VP7 neutralization
specificities to lineage 1 viruses (strains WI61, F45, and
AU32), and (ii) the lineage 3 viruses may have a progenitor
distinct from that of the lineage 1 viruses (Hoshino et al.,
2004). The present study has shown that the VP7 of the
porcine A2 strain is similar, if not identical, to that of
lineage 3 human G9 strains serotypically. In addition, we
have shown by sequence analysis that the A2 VP7 belongs
to phylogenetic lineage 3. Furthermore, the A2 VP7 shares
characteristic amino acid (aa) substitutions with lineage 3
human G9 strains. For example, aa residues 17 (valine), 208(isoleucine), and 250 (lysine) are found only in the A2 and
lineage 3 viruses. Preliminary data obtained from codon
usage bias analysis of the A2 VP7 and that of human G9
viruses belonging to lineage 1–3 shows that the A2 and
lineage 3 G9 viruses share common condon usages distinct
from those exhibited by lineage 1 or 2 viruses (data not
shown). These findings suggest that the porcine G9 virus
and human G9 lineage 3 viruses may have a common
ancestor or perhaps the porcine G9 virus itself may be a
progenitor of contemporary lineage 3 human viruses. In this
regard, it is worthy to note that two lineage 3 G9 strains
(Mc323 and Mc345) isolated from patients with diarrhea in
Thailand in 1989 are postulated to be naturally occurring
porcine–human reassortant rotaviruses since (i) they are
more closely related genetically to porcine than human
rotaviruses as determined by RNA–RNA hybridization; (ii)
the VP4 type (P[19]) of these strains has only been detected
in pigs thus far (Kapikian et al., 2001; Okada et al., 2000);
and (iii) they exhibit a long RNA electropherotype with
subgroup I specificity, rare characteristics to human
rotaviruses (Urasawa et al., 1992). Interestingly, lineages 2
and 3 viruses share certain common aa substitutions (e.g., aa
residues 220 [threonine] and 242 [asparagines]). This
indicates that the lineages 2 and 3 G9 viruses may have
evolved from a common ancestor.
Although rotavirus strain surveillance in the pig pop-
ulation has been performed in various parts of the world, the
detection of G9 porcine rotaviruses has been reported only
in the United States and Brazil thus far (Paul et al., 1988;
Santos et al., 1999; Winiarczyk et al., 2002). In the United
States, the detection of four porcine G9 viruses has been
reported (Paul et al., 1988; Winiarczyk et al., 2002). We
wanted to include such viruses in the present study;
however, unfortunately, these viruses were no longer
available for further characterization. It will be interesting
to continue strain surveillance to determine the prevalence
of G9 viruses in the pig population in the United States as
well as in other parts of the world. It is noteworthy that the
A2 strain of porcine G9 virus characterized in this study was
isolated in the late 1970s to the early 1980s, which makes
the A2 strain (lineage 3 virus) the first G9 rotavirus ever
isolated. It is of interest also to note that the detection of the
first G9 human rotaviruses (lineage 1 virus) was reported in
the United States in 1983. Currently, we are examining
selected archival stool samples from children with diarrhea
collected in Washington, DC, in the 1970s and 1980s to
investigate the distribution of lineage 1 or 3 G9 viruses.
Approximately 2 decades ago, based on the Jennerian
principle, rhesus monkey rotavirus (RRV, MMU18006
strain) was developed as a human rotavirus candidate
vaccine (Kapikian et al., 1985, 2001). That was because
(i) RRV was similar, if not identical in a two-way fashion, to
human G3 rotaviruses (Hoshino et al., 1984), (ii) it bore an
attenuation phenotype in humans, and (iii) it grew to high
titer in primary simian cell cultures (Kapikian et al., 1985).
Although the porcine rotavirus A2 strain could possibly
Y. Hoshino et al. / Virology 332 (2005) 177–188 185provide an attenuation phenotype in humans, unlike RRV, it
would not be an ideal G9 vaccine candidate, because, as we
have shown in this study, antiserum to the A2 virus does not
neutralize lineage 1 G9 viruses efficiently. Thus, in selecting
a vaccine candidate, care must be exercised to select a strain
with the broadest available reactivity to extant serotypes.
Nucleotide sequence accession numbers
Sequence data reported in this work have been deposited
in the GenBank database under accession numbers
AB180972 (A2, VP7 gene), AB180977 (A2, VP8* gene),
and AB180978 (A2, NSP4 gene).Materials and methods
Virus isolation, cell cultures, culture medium, subgroup
assay, neutralization assay, hyperimmune antiserum, and
polyacrylamide gel electrophoresis
Table 1 summarizes the rotavirus strains employed in this
study, which represented G1–G14 specificity. A porcine
rotavirus A2 strain was isolated from a commercial (Ambico)
bivalent live oral rotavirus vaccine for veterinary use as
described previously (Hesse et al., 1993). Human serotype
G9 viruses were strains WI61 (from the United States), F45
(Ikegami et al., 1987), and AU32 (from Japan) (lineage 1);
116E (from India) (lineage 2); and R44, R143 (from Brazil),
US1205 (from the United States), INL1 (from India), and
BD524 (from Bangladesh) (lineage 3). The earliest G9 strain
was isolated in 1983 and the latest was isolated in 1999.
Strains WI61, F45, AU32, 116E, R44, INL1, and BD524 had
a blongQ electropherotype, whereas the strains R143 and
US1205 exhibited a bshortQ electropherotype. Single VP7
gene substitution rotavirus reassortant D  UK (P7[5]:G1)
used in this study was an experimental vaccine suspension
(Lot HDBRV-1) prepared in fetal rhesus monkey lung diploid
cell strain (FRhl-2) cultures (Midthun et al., 1985). Primary
cultures of African green monkey kidney (AGMK) cells
(Diagnostic Hybrids, Athens, OH) or an established monkey
kidney MA104 cell line was used for virus amplification,
genetic reassortment, and plaque purification. The MA104
cell line was used for virus titration and plaque reduction
neutralization (PRN) assay. Eagle’s minimum essential
medium supplemented with 0.5 Ag/ml trypsin (Sigma g-
irradiated trypsin, Sigma Chemical, St. Louis, MO) and
antibiotics was used as maintenance medium, and Leibovitz
L-15 medium (Quality Biological, Gaithersburg, MD)
supplemented with antibiotics was employed when making
virus or serum dilutions. Subgroup specificity of selected
rotavirus strains was determined by subgroup-specific
monoclonal antibody (mAb)-based enzyme-linked immuno-
sorbent assay (ELISA) as previously described (Greenberg
et al., 1983). PRN assay was performed using 50–60
plaque-forming-units per 250 Al of the virus as describedpreviously (Hoshino et al., 1998). Agarose (SeaKem ME,
BMA, Rockland, ME) was used as a solidifying reagent in
the overlay medium. Hyperimmune antiserum to each
rotavirus strain or reassortant was raised in specific
pathogen free guinea pigs (Charles River, Wilmington,
MA) which were free of rotavirus neutralizing antibodies
(titer b1:20 vs. AU32) as determined by PRN assay. Sera
were inactivated before use by heating at 56 8C for 30 min.
Rotavirus immunogens were prepared as described previ-
ously (Hoshino et al., 2004; Wyatt et al., 1982). Rotavirus
genomic double-stranded (ds) RNAs were extracted with a
mixture of phenol/choloroform/isoamyl alcohol (25:24:1 v/v,
GIBCO Invitrogen Corp., Carlsbad, CA), precipitated with
ethanol and analyzed in a 10% polyacrylamide gel as reported
previously (Jones et al., 2003).
Construction, identification, and characterization of single
VP7 gene substitution rotavirus reassortants
Since the interaction of VP4–VP7 outer capsid proteins
of rotavirus has been reported to affect the expression of
selected phenotypes of one or both proteins (Chen et al.,
1992; Pesavento et al., 2003), we constructed reassortants
UK  A2 (P7[5]:G,A2) and DS-1  A2 (P1B[4]:G,A2).
Roller tube cultures of primary AGMK cells were coin-
fected at a multiplicity of infection of approximately one
with the porcine rotavirus A2 strain and the reassortant
rotavirus D  UK. When approximately 75% of the infected
cells exhibited cytopathic effects, the cultures were frozen
and thawed once and the lysate was plated onto MA104
cells in a six-well plate (Costar, Corning Inc., Corning, NY)
in the presence of G1-specific VP7 neutralizing mAb 2C9
(Shaw et al., 1985) for selection of the desired UK  A2
(P7[5]:G,A2) reassortant. The desired single VP7 gene
substitution reassortant was selected and identified and then
plaque purified three times. The plaque purified UK  A2
reassortant was then used to generate the DS-1  A2
(P1B[4]:G,A2) reassortant. A cell culture lysate coinfected
with the UK  A2 reassortant and the DS-1 virus was plated
onto MA104 cells in a six-well plate in the presence of G2-
specific VP7 neutralizing mAb S2-2G10 (Taniguchi et al.,
1987) for selection of the desired single VP7 gene
substitution reassortant DS-1  A2 (P1B[4]:G,A2). The
origin of genes of each reassortant was identified by
polyacrylamide gel electrophoresis (PAGE) of its genomic
dsRNAs (Kalica et al., 1978; Rodger and Holmes, 1979).
Genomic RNAs were electrophoresed at 13 mA for 15 h and
the resulting migration patterns were visualized by staining
of gel with silver nitrate. The origin of certain genes that
was not able to be determined with certainty by PAGE was
studied further by constant denaturant gel electrophoresis as
previously described (Jones et al., 2003). Hyperimmune
guinea pig antiserum to each rotavirus strain or reassortant
was analyzed for VP7- and VP4-specific antibodies to
selected human and animal rotavirus strains or reassortants
by 60% PRN assay.
Y. Hoshino et al. / Virology 332 (2005) 177–188186Nucleotide sequence analysis of the VP7, VP8*, and NSP4
genes of porcine A2 strain and phylogenetic analysis
A full-length cDNA of the VP7 or NSP4 gene, or 876
base pairs (bp) of the VP4 fragment of the A2 strain was
amplified using primer pair Beg9 and End9 (Gouvea et al.,
1990) (for VP7 gene), Wa10F (5VGGCTTTTAAAAGTTCT
GTTC 3V) andWa10R (5VGGTCACACTAAGACCATTCC
3V) (for the NSP4 gene), or con2 and con3 (Gentsch et al.,
1992) (for 876-bp fragment of VP4). The amplified product
from RT-PCR was separated by electrophoresis in a 1%
agarose gel, recovered from the gel, purified with a Wizard
SV gel and PCR clean-up kit (Promega) as indicated by the
manufacturer, and cloned into the pCR2.1-TOPO vector
(Invitrogen). The recombinant plasmids were introduced into
E. coli TOP 10 strain (Invitrogen) and recovered using
QIAprep spin miniprep kit (Qiagen). Two independent
cDNA clones with the desired VP7 gene, VP8* gene, or
NSP4 gene insert were sequenced at least twice using the
BigDye terminator cycle sequencing kit (Applied Biosys-
tems) with M13 forward and reverse primers and the ABI
PRISM 310 automated DNA sequencer. Sequence alignment
was carried out with DNASIS software (Hitachi software)
and phylogenetic analyses were made using UPGMA
method with the MacVecter 7.1 program (Accelrys Inc.).Acknowledgments
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